Icofungipen (PLIVA).
Icofungipen is a cyclic beta-amino acid being development by PLIVA, under license from Bayer, for the potential oral treatment of fungal infection. As of September 2002, the first phase II efficacy study was underway.
Yeates
Clive
C
InPharma, Welwyn, Hertfordshire, UK. cly@inpharma.co.uk
D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D003515:Cycloleucine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D013329:Structure-Activity Relationship
D000935:Antifungal Agents; D003515:Cycloleucine; C114614:2-amino-4-methylenecyclopentane-1-carboxylic acid